Jenny R. Robertson, J.D., served as Chief Legal Officer at Lexeo Therapeutics Inc., a clinical-stage biotechnology company advancing gene therapies for cardiovascular and neurodegenerative diseases. In this role, she provided strategic legal oversight, managing all aspects of corporate governance, regulatory compliance, intellectual property, and commercial transactions during a period of rapid growth and clinical advancement. Jenny's leadership was instrumental in guiding the company through its transformative public listing via SPAC merger in 2023, ensuring seamless execution amid complex securities and FDA requirements. With over two decades of experience in life sciences law, Jenny previously held senior legal positions at leading biotech firms, including General Counsel at a venture-backed gene therapy startup where she spearheaded multiple licensing deals and Series B/C financings exceeding $300 million. Earlier in her career, she practiced at premier law firms such as Cooley LLP and Goodwin Procter, focusing on M&A, venture capital, and emerging companies in the pharmaceutical sector. A cum laude graduate of Harvard Law School, Jenny also holds a B.A. in Biology from Duke University, blending her scientific acumen with legal expertise. Jenny's achievements include negotiating groundbreaking partnerships with major pharmaceutical collaborators and successfully defending key patents in international arbitrations, which bolstered Lexeo's pipeline of investigational therapies. Recognized as a "Life Sciences Trailblazer" by The Legal 500, she championed diversity initiatives in biotech legal teams and authored influential publications on gene therapy regulation. Her tenure at Lexeo solidified the company's robust legal foundation, positioning it for long-term success in precision medicine.